[O5] Oral Session 5　Breast Cancer
【E】

[O5-1] Endocrine maintenance strategy with Capecitabine after BEV+PTX induction for HR+HER2- met. Breast Cancer: KBCSG-TR1214

^○Tetsuhiro Yoshinami^1,10, Norikazu Masuda², Masahiko Ikeda³, Makiko Mizutani², Miki Yamaguchi⁴, Yoshifumi Komoike⁵, Tsutomu Takashima⁶, Katsuhide Yoshidome⁷, Junji Tsurutani⁸, Mitsuhiko Iwamoto⁹, Fumie Fujisawa¹⁰, Hiroyuki Yasojima², Jun Yamamura¹¹, Hirotaka Morishima¹², Fuminori Aki¹³, Tomomi Yamada¹⁴, Satoshi Morita¹⁵, Takahiro Nakayama¹⁶ (1.Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2.Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, 3.Department of Breast and Thyroid Surgery, Fukuyama City Hospital, 4.Department of Breast Surgery, JCHO Kurume General Hospital, 5.Department of Medicine, Kindai University Hospital, 6.Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka City University, 7.Department of Breast and Endocrine Surgery, Osaka Police Hospital, 8.Advanced Cancer Translation Research Institute, Showa University, 9.Breast and Endocrine Surgery, Osaka Medical College, 10.Department of Medical Oncology, Osaka International Cancer Institute, 11.Department of Surgery, Sakai City Medical Center, 12.Department of Breast Surgery, Osaka Rosai Hospital, 13.Ito Surgical Mammary Gland Clinic, 14.Department of Medical Innovation, Osaka University Hospital, 15.Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 16.Department of Breast and Endocrine Surgery, Osaka International Cancer Institute)